FivePrime Reports Discovery of IL-34 SAN FRANCISCO, California – May 8, 2008. In this week’s edition of the journal Science, researchers at Five Prime Therapeutics, Inc. report the discovery of Interleukin‐34, a novel cytokine, as well as the identification of an IL‐34 receptor.
FivePrime achieves target discovery milestone with Boehringer Ingelheim SAN FRANCISCO, California - October 01, 2007 , Five Prime Therapeutics, Inc., the protein therapeutics discovery and development company, today announced that it has successfully achieved a target discovery milestone in its
FivePrime enters Osteoarthritis and Pulmonary Fibrosis Collaboration with Centocor San Francisco, California – January 3, 2007 . Five Prime Therapeutics, Inc. today announced a worldwide collaborative research and license agreement with Centocor Research and Development Inc.
Mark McDade to join FivePrime Board of Directors San Francisco - Five Prime Therapeutics, Inc. today announced that it has appointed Mark McDade, CEO of PDL BioPharma, Inc, to the FivePrime Board of Directors. “We are delighted to have Mark join our Board”, said Lewis T.
FivePrime and Boehringer Ingelhein Initiate Rheumatoid Arthritis Collaboration San Francisco - Five Prime Therapeutics, Inc. announced today to have entered into a two year collaborative research and license agreement with Boehringer Ingelheim to discover novel therapeutic products to treat
Biosite and FivePrime Announce Antibody Collaboration SAN DIEGO and SAN FRANCISCO—Biosite® Incorporated (Nasdaq: BSTE) and Five Prime Therapeutics, Inc. have entered into a collaboration for the evaluation of disease targets for potential commercialization of diagnostic and therapeutic products.